Global CAR T-Cell therapy Market Size study & Forecast, by Indication (Lymphoma, Acute Lymphocytic Leukemia, Others), By Drug Type (Axicabtagene Ciloleucel, Tisagenlecleucel, Brexucabtagene Autoleucel, Others), By End user (Hospitals, Cancer Treatment Cen

Global CAR T-Cell therapy Market Size study & Forecast, by Indication (Lymphoma, Acute Lymphocytic Leukemia, Others), By Drug Type (Axicabtagene Ciloleucel, Tisagenlecleucel, Brexucabtagene Autoleucel, Others), By End user (Hospitals, Cancer Treatment Centers), and Regional Analysis, 2023-2030

Global CAR T-Cell therapy Market is valued at approximately USD 1.93 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 13.5% over the forecast period 2023-2030. Chimeric antigen receptor (CAR) T cell therapy is a novel form of cancer therapy in which medical experts modify T cells in a lab before injecting them into cancer patients' bodies to enable them to detect and eliminate cancer cells. The immune system is trained to recognize malignant cells by CAR T-cell therapy. The immune response against malignant cells is boosted by CAR T-cell treatment. The market for CAR T-cell therapy is primarily driven by an increase in the demand for suitable therapeutics for the treatment of cancer, favorable reimbursement policies for CAR T-cell therapy medications in some countries, and an increase in consumer awareness of CAR T-cell therapy medications. Additionally, the recent commercialization of CAR-T cell therapy and the surging clinical trial activities are further influencing the market expansion.

In addition, an increase in the incidence of cancer such as leukemia and lymphoma are directly augmenting the demand for CAR T-Cell therapy. According to World Health Organization (WHO), in 2020, the number of leukemia cancer cases is estimated to account for 475 thousand, which is projected to reach 692 thousand patients by the year 2040. Accordingly, the growing prevalence of cancer is fueling the demand for a wide range of diagnosis and treatment alternatives, which, in turn, accelerates the growth of the CAR T-Cell therapy Market. Moreover, the growing investment in research and development, as well as increasing advancements in technology present various lucrative opportunities over the forecasting years. However, the unavailability of skilled professionals and the high cost of developing CAR T-cell therapy are challenging the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global CAR T-Cell therapy Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the increasing regulatory approvals, growing investment in advancing healthcare facilities, and rising technological developments. Whereas, Asia Pacific is expected to grow at the highest CAGR over the forecasting years. The rising prevalence of cancer, increasing research funding for novel therapeutics by government bodies, and growing awareness and increase in approval of novel medications are significantly propelling the market demand across the region.

Major market players included in this report are:
Autolus Therapeutics
Bluebird bio, Inc.
Bristol-Myers Squibb
Caribou Biosciences, Inc.
Cartesian Therapeutics, Inc.
Celgene Corporation
Gilead Sciences, Inc. (Kite Pharma Inc.)
Merck & Co., Inc.
Novartis AG
Pfizer, Inc.

Recent Developments in the Market:
 In June 2022, Bristol-Myers Squibb Company announced that the company received the U.S. Food and Drug Administration (FDA) approval for Breyanzi CAR T cell therapy to cure refractory or relapsed large B-cell lymphoma after one prior therapy. The Phase 2 pilot company-sponsored research of a CAR T cell treatment in patients with primary refractory or relapsed LBCL served as the foundation for the approval.
 In February 2022, Johnson & Johnson Services, Inc. declared that the U.S. Food and Drug Administration had approved CARVYKTI (ciltacabtagene autoleucel), a BCMA-Directed CAR-T Immunotherapy for the treatment of Patients with Relapsed or Refractory Multiple Myeloma.

Global CAR T-Cell therapy Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered - Indication, Drug type, End user, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Indication:
Lymphoma
Acute Lymphocytic Leukemia
Others

By Drug type:
Axicabtagene Ciloleucel
Tisagenlecleucel
Brexucabtagene Autoleucel
Others

By End-user:
Hospitals
Cancer Treatment Centers

By Region:
North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned

Autolus Therapeutics
Bluebird bio, Inc.
Bristol-Myers Squibb
Caribou Biosciences, Inc.
Cartesian Therapeutics, Inc.
Celgene Corporation
Gilead Sciences, Inc. (Kite Pharma Inc.)
Merck & Co., Inc.
Novartis AG
Pfizer, Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.